RXRX insider transactions
Recursion Pharmaceuticals Inc. (RXRX) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
Recent Form 3, 4, and 5 filings for RXRX
- Director Gibson Christopher converted options into 40,000 shares and sold $144,800 worth of shares (40,000 units at $3.62) as part of a pre-agreed trading plan (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- CEO and President Khan Najat sold $84,459 worth of shares (23,588 units at $3.58) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 2,175,796 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Director Bumpus Namandje sold $15,526 worth of shares (4,386 units at $3.54) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 43,171 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Director Borgeson Blake sold $110,400 worth of shares (30,000 units at $3.68) as part of a pre-agreed trading plan, decreasing direct ownership by 0.48% to 6,169,863 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Director Gibson Christopher converted options into 40,000 shares and sold $123,200 worth of shares (40,000 units at $3.08) as part of a pre-agreed trading plan (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- CEO and President Khan Najat covered exercise/tax liability with 62,701 shares, decreasing direct ownership by 3% to 2,199,384 units (SEC Form 4) (for withholding tax)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Chief Scientific Officer Hallett David covered exercise/tax liability with 26,657 shares, decreasing direct ownership by 2% to 1,070,494 units (SEC Form 4) to cover withholding tax4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Director Gibson Christopher covered exercise/tax liability with 22,821 shares, decreasing direct ownership by 3% to 883,735 units (SEC Form 4) (for tax liability)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Chief Financial Officer Taylor Ben R covered exercise/tax liability with 25,018 shares, decreasing direct ownership by 2% to 1,107,272 units (SEC Form 4) to cover withholding tax4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Director Gibson Christopher converted options into 60,000 shares, sold $134,800 worth of shares (40,000 units at $3.37) as part of a pre-agreed trading plan and gifted 20,000 shares (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Director Borgeson Blake sold $105,600 worth of shares (30,000 units at $3.52) as part of a pre-agreed trading plan, decreasing direct ownership by 0.48% to 6,199,863 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Director Gibson Christopher converted options into 40,000 shares and sold $144,400 worth of shares (40,000 units at $3.61) as part of a pre-agreed trading plan (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- SEC Form 4 filed by Taylor Ben R4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- SEC Form 4 filed by Gibson Christopher4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- SEC Form 4 filed by Borgeson Blake4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- SEC Form 4 filed by Dar Zavain4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- SEC Form 4 filed by Li Dean Y4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- SEC Form 4 filed by Gibson Christopher4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- SEC Form 4 filed by Taylor Ben R4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Director Gibson Christopher converted options into 20,000 shares and gifted 20,000 shares (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- CEO and President Khan Najat sold $94,660 worth of shares (28,298 units at $3.35), decreasing direct ownership by 1% to 2,262,085 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Director Borgeson Blake sold $588,200 worth of shares (170,000 units at $3.46), decreasing direct ownership by 3% to 6,259,863 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Director Gibson Christopher converted options into 40,000 shares, sold $138,400 worth of shares (40,000 units at $3.46) and covered exercise/tax liability with 27,265 shares, decreasing direct ownership by 3% to 906,556 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Chief Scientific Officer Hallett David covered exercise/tax liability with 11,908 shares, decreasing direct ownership by 1% to 1,097,151 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Chief Financial Officer Taylor Ben R covered exercise/tax liability with 11,908 shares and sold $41,352 worth of shares (13,426 units at $3.08), decreasing direct ownership by 2% to 1,195,349 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- CEO and President Khan Najat covered exercise/tax liability with 14,280 shares, decreasing direct ownership by 0.62% to 2,290,383 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- CEO and President Khan Najat was granted 1,703,892 shares and covered exercise/tax liability with 10,364 shares, increasing direct ownership by 277% to 2,304,663 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Chief Financial Officer Taylor Ben R was granted 470,533 shares and covered exercise/tax liability with 11,400 shares, increasing direct ownership by 60% to 1,220,683 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Chief Scientific Officer Hallett David was granted 526,318 shares and covered exercise/tax liability with 11,400 shares, increasing direct ownership by 87% to 1,109,059 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Director Gibson Christopher converted options into 40,000 shares, sold $164,800 worth of shares (40,000 units at $4.12), was granted 30,346 shares and covered exercise/tax liability with 10,364 shares, increasing direct ownership by 2% to 933,821 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Director Borgeson Blake sold $924,000 worth of shares (220,000 units at $4.20), decreasing direct ownership by 3% to 6,429,863 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Director Gibson Christopher converted options into 40,000 shares and sold $178,800 worth of shares (40,000 units at $4.47) (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- New insider Hallett David claimed ownership of 594,141 shares (SEC Form 3)3 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Director Borgeson Blake sold $959,200 worth of shares (220,000 units at $4.36), decreasing direct ownership by 3% to 6,649,863 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Director Gibson Christopher converted options into 60,000 shares, sold $170,000 worth of shares (40,000 units at $4.25) and gifted 20,000 shares (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Director Dar Zavain was granted 3,571 shares, increasing direct ownership by 3% to 142,329 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Director Li Dean Y was granted 2,381 shares, increasing direct ownership by 0.19% to 1,240,909 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Chief Financial Officer Taylor Ben R sold $89,381 worth of shares (21,383 units at $4.18), decreasing direct ownership by 3% to 761,550 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Chief R&D Commercial Officer Khan Najat sold $548,592 worth of shares (124,403 units at $4.41), decreasing direct ownership by 17% to 611,135 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Chief Executive Officer Gibson Christopher converted options into 40,000 shares and sold $180,000 worth of shares (40,000 units at $4.50) (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Chief Financial Officer Taylor Ben R covered exercise/tax liability with 7,057 shares, decreasing direct ownership by 0.89% to 782,933 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Chief Executive Officer Gibson Christopher converted options into 60,000 shares, sold $185,200 worth of shares (40,000 units at $4.63) and gifted 20,000 shares (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Director Borgeson Blake sold $961,400 worth of shares (220,000 units at $4.37), decreasing direct ownership by 3% to 6,869,863 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Chief Financial Officer Taylor Ben R covered exercise/tax liability with 2,271 shares, decreasing direct ownership by 0.29% to 789,990 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Chief Financial Officer Taylor Ben R covered exercise/tax liability with 11,908 shares, decreasing direct ownership by 1% to 792,261 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Chief R&D Commercial Officer Khan Najat covered exercise/tax liability with 17,584 shares, decreasing direct ownership by 2% to 735,538 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Chief Executive Officer Gibson Christopher covered exercise/tax liability with 40,390 shares, converted options into 40,000 shares and sold $166,400 worth of shares (40,000 units at $4.16), decreasing direct ownership by 4% to 913,839 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Chief R&D Commercial Officer Khan Najat was granted 84,925 shares, increasing direct ownership by 13% to 753,122 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Chief Executive Officer Gibson Christopher converted options into 60,000 shares, sold $208,400 worth of shares (40,000 units at $5.21) and gifted 20,000 shares (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Chief Executive Officer Gibson Christopher converted options into 100,000 shares and sold $570,000 worth of shares (100,000 units at $5.70) (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Chief Executive Officer Gibson Christopher converted options into 120,000 shares, sold $604,000 worth of shares (100,000 units at $6.04) and gifted 20,000 shares (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Director Li Dean Y was granted 1,961 shares, increasing direct ownership by 0.16% to 1,238,528 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Director Dar Zavain was granted 2,941 shares, increasing direct ownership by 2% to 138,758 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Chief Executive Officer Gibson Christopher converted options into 100,000 shares and sold $476,000 worth of shares (100,000 units at $4.76) (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Chief Financial Officer Taylor Ben R covered exercise/tax liability with 7,057 shares, decreasing direct ownership by 0.87% to 804,169 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Chief Executive Officer Gibson Christopher converted options into 120,000 shares, sold $471,000 worth of shares (100,000 units at $4.71) and gifted 20,000 shares (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Chief Executive Officer Gibson Christopher converted options into 100,000 shares and sold $484,000 worth of shares (100,000 units at $4.84) (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Chief Financial Officer Taylor Ben R covered exercise/tax liability with 11,908 shares, decreasing direct ownership by 1% to 811,226 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Chief Executive Officer Gibson Christopher covered exercise/tax liability with 40,390 shares, decreasing direct ownership by 4% to 954,229 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- Chief R&D Commercial Officer Khan Najat covered exercise/tax liability with 3,789 shares and sold $202,173 worth of shares (36,599 units at $5.52), decreasing direct ownership by 6% to 668,197 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)